On June 27, Coherus Biosciences announced the sale of Yusimry, its low-concentration biosimilar of adalimumab, to a Chinese company for $40 million. The buyer’s US subsidiary, Meitheal Pharmaceuticals, will take over all US commercial activities after the purchase of Yusimry. According to Meitheal’s press release, they expect “additional indications, including a high-concentration formulation, to be … Continue reading Coherus Exits the Adalimumab Biosimilar Market With Sale of Yusimry®